Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Chronic hypergastrinemia: causes and consequences.

Orlando LA, Lenard L, Orlando RC.

Dig Dis Sci. 2007 Oct;52(10):2482-9. Epub 2007 Apr 6. Review.

PMID:
17415644
2.

Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors.

Banasch M, Schmitz F.

Wien Klin Wochenschr. 2007;119(19-20):573-8.

PMID:
17985090
3.
4.

Diagnosis and differential diagnosis of hypergastrinemia.

Arnold R.

Wien Klin Wochenschr. 2007;119(19-20):564-9. Review.

PMID:
17985088
5.

Pathobiology and management of hypergastrinemia and the Zollinger-Ellison syndrome.

Hirschowitz BI.

Yale J Biol Med. 1992 Nov-Dec;65(6):659-76; discussion 689-92. Review.

6.

Discussion on the effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas.

Cattan D.

Gastroenterology. 2003 Aug;125(2):627; author reply 627-8. No abstract available.

PMID:
12891576
8.
9.

Hypergastrinemia--diagnosis and treatment.

Niederle B.

Wien Klin Wochenschr. 2007;119(19-20):561-3. No abstract available.

PMID:
17985087
10.

Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients.

Delle Fave G, Marignani M, Corleto VD, Angeletti S, D'Ambra G, Ferraro G, D'Adda T, Azzoni C, Jensen RT, Annibale B, Bordi C.

Dig Liver Dis. 2002 Apr;34(4):270-8.

PMID:
12038811
11.

Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas.

Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, Venzon DJ, Delle Fave G, Bordi C, Jensen RT.

Gastroenterology. 2002 Jul;123(1):68-85.

PMID:
12105835
12.

Zollinger-Ellison syndrome in 2006: concepts from a clinical point of view.

Pellicano R, De Angelis C, Resegotti A, Rizzetto M.

Panminerva Med. 2006 Mar;48(1):33-40. Review.

PMID:
16633330
13.

Considerations for long-term use of proton-pump inhibitors.

Garnett WR.

Am J Health Syst Pharm. 1998 Nov 1;55(21):2268-79. Review.

PMID:
9825878
14.

Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.

Tomassetti P, Salomone T, Migliori M, Campana D, Corinaldesi R.

Drugs Aging. 2003;20(14):1019-34. Review.

PMID:
14651442
15.

Assessment of the risk of iatrogenic hypergastrinaemia from patients with gastrinoma.

Waldum H.

Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):3. No abstract available.

16.

Pseudo-Zollinger--Ellison syndrome in a child presenting with anemia.

Zaatar R, Younoszai MK, Mitros F.

Gastroenterology. 1987 Feb;92(2):508-12.

PMID:
3792786
17.

[Clinical value of determining pepsinogen I].

Griessen M, Male PJ, Infante F, Jodry H, Loizeau E.

Schweiz Med Wochenschr. 1984 Dec 8;114(49):1849-51. French.

PMID:
6515384
18.

Gastrin-physiological and pathophysiological role: clinical consequences.

Waldum HL, Brenna E, Kleveland PM, Sandvik AK.

Dig Dis. 1995 Jan-Feb;13(1):25-38. Review.

PMID:
7606834
19.

Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor.

Desai AA, McGuigan JE, Draganov P.

Int J Gastrointest Cancer. 2005;35(2):157-61.

PMID:
15879632
20.

Marked hypergastrinemia in gastric outlet obstruction.

Hangen D, Maltz GS, Anderson JE, Knauer CM.

J Clin Gastroenterol. 1989 Aug;11(4):442-4.

PMID:
2760432

Supplemental Content

Support Center